193 results on '"Limacher, Jean Marc"'
Search Results
2. Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak
- Author
-
Martin, Sophie, Pflumio, Carole, Trensz, Philippe, Schaff-Wendling, Frederique, Weindling, Michal Kalish, Fischbach, Cathie, Pierard, Laure, Limacher, Jean-Marc, Nader, Rita, Velten, Michel, and Petit, Thierry
- Published
- 2023
- Full Text
- View/download PDF
3. Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease
- Author
-
Jiao, Yue, Truong, Thérèse, Eon-Marchais, Séverine, Mebirouk, Noura, Caputo, Sandrine M., Dondon, Marie-Gabrielle, Karimi, Mojgan, Le Gal, Dorothée, Beauvallet, Juana, Le Floch, Édith, Dandine-Roulland, Claire, Bacq-Daian, Delphine, Olaso, Robert, Albuisson, Juliette, Audebert-Bellanger, Séverine, Berthet, Pascaline, Bonadona, Valérie, Buecher, Bruno, Caron, Olivier, Cavaillé, Mathias, Chiesa, Jean, Colas, Chrystelle, Collonge-Rame, Marie-Agnès, Coupier, Isabelle, Delnatte, Capucine, De Pauw, Antoine, Dreyfus, Hélène, Fert-Ferrer, Sandra, Gauthier-Villars, Marion, Gesta, Paul, Giraud, Sophie, Gladieff, Laurence, Golmard, Lisa, Lasset, Christine, Lejeune-Dumoulin, Sophie, Léoné, Mélanie, Limacher, Jean-Marc, Lortholary, Alain, Luporsi, Élisabeth, Mari, Véronique, Maugard, Christine M., Mortemousque, Isabelle, Mouret-Fourme, Emmanuelle, Nambot, Sophie, Noguès, Catherine, Popovici, Cornel, Prieur, Fabienne, Pujol, Pascal, Sevenet, Nicolas, Sobol, Hagay, Toulas, Christine, Uhrhammer, Nancy, Vaur, Dominique, Venat, Laurence, Boland-Augé, Anne, Guénel, Pascal, Deleuze, Jean-François, Stoppa-Lyonnet, Dominique, Andrieu, Nadine, and Lesueur, Fabienne
- Published
- 2023
- Full Text
- View/download PDF
4. Combining the potency of a neoantigen-expressing DNA vector, an anti-CTLA-4 antibody, and an attenuated poxvirus in a personalized immunization platform: Preclinical studies of ODI-2001.
- Author
-
Marschall, Pierre, primary, Matta, Celia, additional, Hugel, Cécile, additional, Matta, Jessica, additional, Bogaert, Cedric, additional, Ghiringhelli, François, additional, Balducchi, Pascale, additional, and Limacher, Jean-Marc, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach
- Author
-
Caputo, Sandrine M., Golmard, Lisa, Léone, Mélanie, Damiola, Francesca, Guillaud-Bataille, Marine, Revillion, Françoise, Rouleau, Etienne, Derive, Nicolas, Buisson, Adrien, Basset, Noémie, Schwartz, Mathias, Vilquin, Paul, Garrec, Celine, Privat, Maud, Gay-Bellile, Mathilde, Abadie, Caroline, Abidallah, Khadija, Airaud, Fabrice, Allary, Anne-Sophie, Barouk-Simonet, Emmanuelle, Belotti, Muriel, Benigni, Charlotte, Benusiglio, Patrick R., Berthemin, Christelle, Berthet, Pascaline, Bertrand, Ophelie, Bézieau, Stéphane, Bidart, Marie, Bignon, Yves-Jean, Birot, Anne-Marie, Blanluet, Maud, Bloucard, Amelie, Bombled, Johny, Bonadona, Valerie, Bonnet, Françoise, Bonnet-Dupeyron, Marie-Noëlle, Boulaire, Manon, Boulouard, Flavie, Bouras, Ahmed, Bourdon, Violaine, Brahimi, Afane, Brayotel, Fanny, Bressac de Paillerets, Brigitte, Bronnec, Noémie, Bubien, Virginie, Buecher, Bruno, Cabaret, Odile, Carriere, Jennifer, Chiesa, Jean, Chieze-Valéro, Stephanie, Cohen, Camille, Cohen-Haguenauer, Odile, Colas, Chrystelle, Collonge-Rame, Marie-Agnès, Conoy, Anne-Laure, Coulet, Florence, Coupier, Isabelle, Crivelli, Louise, Cusin, Véronica, De Pauw, Antoine, Dehainault, Catherine, Delhomelle, Hélène, Delnatte, Capucine, Demontety, Sophie, Denizeau, Philippe, Devulder, Pierre, Dreyfus, Helene, d’Enghein, Catherine Dubois, Dupré, Anaïs, Durlach, Anne, Dussart, Sophie, Fajac, Anne, Fekairi, Samira, Fert-Ferrer, Sandra, Fiévet, Alice, Fouillet, Robin, Mouret-Fourme, Emmanuelle, Gauthier-Villars, Marion, Gesta, Paul, Giraud, Sophie, Gladieff, Laurence, Goldbarg, Veronica, Goussot, Vincent, Guibert, Virginie, Guillerm, Erell, Guy, Christophe, Hardouin, Agnès, Heude, Céline, Houdayer, Claude, Ingster, Olivier, Jacquot-Sawka, Caroline, Jones, Natalie, Krieger, Sophie, Lacoste, Sofiane, Lallaoui, Hakima, Larbre, Helene, Laugé, Anthony, Le Guyadec, Gabrielle, Le Mentec, Marine, Lecerf, Caroline, Le Gall, Jessica, Legendre, Bérengère, Legrand, Clémentine, Legros, Angélina, Lejeune, Sophie, Lidereau, Rosette, Lignon, Norbert, Limacher, Jean-Marc, Doriane Livon, Lizard, Sarab, Longy, Michel, Lortholary, Alain, Macquere, Pierre, Mailliez, Audrey, Malsa, Sarah, Margot, Henri, Mari, Véronique, Maugard, Christine, Meira, Cindy, Menjard, Julie, Molière, Diane, Moncoutier, Virginie, Moretta-Serra, Jessica, Muller, Etienne, Nevière, Zoe, Nguyen Minh Tuan, Thien-vu, Noguchi, Tetsuro, Noguès, Catherine, Oca, Florine, Popovici, Cornel, Prieur, Fabienne, Raad, Sabine, Rey, Jean-Marc, Ricou, Agathe, Salle, Lucie, Saule, Claire, Sevenet, Nicolas, Simaga, Fatoumata, Sobol, Hagay, Suybeng, Voreak, Tennevet, Isabelle, Tenreiro, Henrique, Tinat, Julie, Toulas, Christine, Turbiez, Isabelle, Uhrhammer, Nancy, Vande Perre, Pierre, Vaur, Dominique, Venat, Laurence, Viellard, Nicolas, Villy, Marie-Charlotte, Warcoin, Mathilde, Yvard, Alice, Zattara, Helene, Caron, Olivier, Lasset, Christine, Remenieras, Audrey, Boutry-Kryza, Nadia, Castéra, Laurent, and Stoppa-Lyonnet, Dominique
- Published
- 2021
- Full Text
- View/download PDF
6. Case Report: Fatal Pneumocystis jirovecii Infection in an Elderly Man Receiving Adjuvant Paclitaxel and Trastuzumab Therapy for HER2-Positive Breast Cancer
- Author
-
Vercueil, Colin, primary, Ouaz, Hamza, additional, Schultz, Émilie, additional, and Limacher, Jean-Marc, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation
- Author
-
Ribeiro Guerra, Maximiliano, Coignard, Juliette, Eon-Marchais, Séverine, Dondon, Marie-Gabrielle, Le Gal, Dorothée, Beauvallet, Juana, Mebirouk, Noura, Belotti, Muriel, Caron, Olivier, Gauthier-Villars, Marion, Coupier, Isabelle, Buecher, Bruno, Lortholary, Alain, Fricker, Jean-Pierre, Gesta, Paul, Noguès, Catherine, Faivre, Laurence, Berthet, Pascaline, Luporsi, Elisabeth, Delnatte, Capucine, Bonadona, Valérie, Maugard, Christine M., Pujol, Pascal, Lasset, Christine, Longy, Michel, Bignon, Yves-Jean, Adenis-Lavignasse, Claude, Venat-Bouvet, Laurence, Dreyfus, Hélène, Gladieff, Laurence, Mortemousque, Isabelle, Audebert-Bellanger, Séverine, Soubrier, Florent, Giraud, Sophie, Lejeune-Dumoulin, Sophie, Limacher, Jean-Marc, Chiesa, Jean, Fajac, Anne, Floquet, Anne, Eisinger, François, Tinat, Julie, Fert-Ferrer, Sandra, Colas, Chrystelle, Frebourg, Thierry, Damiola, Francesca, Barjhoux, Laure, Cavaciuti, Eve, Mazoyer, Sylvie, Tardivon, Anne, Lesueur, Fabienne, Stoppa-Lyonnet, Dominique, and Andrieu, Nadine
- Published
- 2021
- Full Text
- View/download PDF
8. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
- Author
-
Harper, Diane M., Nieminen, Pekka, Donders, Gilbert, Einstein, Mark H., Garcia, Francisco, Huh, Warner K., Stoler, Mark H., Glavini, Katerina, Attley, Gemma, Limacher, Jean-Marc, Bastien, Berangere, and Calleja, Elizabeth
- Published
- 2019
- Full Text
- View/download PDF
9. 17. Virus oncolytiques dans le traitement du cancer
- Author
-
Foloppe, Johann, primary, Fend, Laetitia, additional, Préville, Xavier, additional, Erbs, Philippe, additional, and Limacher, Jean-Marc, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour
- Author
-
Acres, Bruce, Lacoste, Gisele, Limacher, Jean-Marc, Compans, Richard W, Series editor, Honjo, Tasuku, Series editor, Oldstone, Michael B. A., Series editor, Vogt, Peter K., Series editor, Malissen, Bernard, Series editor, Aktories, Klaus, Series editor, Kawaoka, Yoshihiro, Series editor, Rappuoli, Rino, Series editor, Galan, Jorge E., Series editor, Ahmed, Rafi, Series editor, Palme, Klaus, Series editor, Casadevall, Arturo, Series editor, Garcia-Sastre, Adolfo, Series editor, Savelyeva, Natalia, editor, and Ottensmeier, Christian, editor
- Published
- 2017
- Full Text
- View/download PDF
11. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
- Author
-
Quoix, Elisabeth, Lena, Hervé, Losonczy, Gyorgy, Forget, Frédéric, Chouaid, Christos, Papai, Zsolt, Gervais, Radj, Ottensmeier, Christian, Szczesna, Aleksandra, Kazarnowicz, Andrzej, Beck, Joseph T, Westeel, Virginie, Felip, Enriqueta, Debieuvre, Didier, Madroszyk, Anne, Adam, Julien, Lacoste, Gisèle, Tavernaro, Annette, Bastien, Bérangère, Halluard, Céline, Palanché, Tania, and Limacher, Jean-Marc
- Published
- 2016
- Full Text
- View/download PDF
12. Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection
- Author
-
Di Bisceglie, Adrian M., Janczweska–Kazek, Ewa, Habersetzer, François, Mazur, Wlodzimierz, Stanciu, Carol, Carreno, Vicente, Tanasescu, Coman, Flisiak, Robert, Romero–Gomez, Manuel, Fich, Alexander, Bataille, Vincent, Toh, Myew–Ling, Hennequi, Marie, Zerr, Patricia, Honnet, Géraldine, Inchauspé, Geneviève, Agathon, Delphine, Limacher, Jean–Marc, and Wedemeyer, Heiner
- Published
- 2014
- Full Text
- View/download PDF
13. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients
- Author
-
Khammari, Amir, Nguyen, Jean-Michel, Saint-Jean, Melanie, Knol, Anne-Chantal, Pandolfino, Marie-Christine, Quereux, Gaelle, Brocard, Anabelle, Peuvrel, Lucie, Saiagh, Soraya, Bataille, Vincent, Limacher, Jean-Marc, and Dreno, Brigitte
- Published
- 2015
- Full Text
- View/download PDF
14. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- Author
-
Quoix, Elisabeth, Ramlau, Rodryg, Westeel, Virginie, Papai, Zsolt, Madroszyk, Anne, Riviere, Alain, Koralewski, Piotr, Breton, Jean-Luc, Stoelben, Erich, Braun, Denis, Debieuvre, Didier, Lena, Hervé, Buyse, Marc, Chenard, Marie-Pierre, Acres, Bruce, Lacoste, Gisèle, Bastien, Bérangère, Tavernaro, Annette, Bizouarne, Nadine, Bonnefoy, Jean-Yves, and Limacher, Jean-Marc
- Published
- 2011
- Full Text
- View/download PDF
15. A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C
- Author
-
Habersetzer, François, Honnet, Géraldine, Bain, Christine, Maynard–Muet, Marianne, Leroy, Vincent, Zarski, Jean–Pierre, Feray, Cyrille, Baumert, Thomas F., Bronowicki, Jean–Pierre, Doffoël, Michel, Trépo, Christian, Agathon, Delphine, Toh, Myew–Ling, Baudin, Martine, Bonnefoy, Jean–Yves, Limacher, Jean–Marc, and Inchauspé, Geneviève
- Published
- 2011
- Full Text
- View/download PDF
16. Immunotherapy for non-small-cell lung cancer: current approaches
- Author
-
Quoix, Elisabeth and Limacher, Jean Marc
- Published
- 2014
- Full Text
- View/download PDF
17. Abstract P1-17-07: Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak
- Author
-
Martin, Sophie, primary, Pflumio, Carole, additional, Trensz, Philippe, additional, Schaff-Wendling, Frederique, additional, Kalish, Michal, additional, Fischbach, Cathie, additional, Pierard, Laure, additional, Limacher, Jean-Marc, additional, Velten, Michel, additional, and Petit, Thierry, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I
- Author
-
Sebai, Molka, primary, Tulasne, David, additional, Caputo, Sandrine M., additional, Verkarre, Virginie, additional, Fernandes, Marie, additional, Guérin, Célia, additional, Reinhart, Fanny, additional, Adams, Séverine, additional, Maugard, Christine, additional, Caron, Olivier, additional, Guillaud‐Bataille, Marine, additional, Berthet, Pascaline, additional, Bignon, Yves‐Jean, additional, Bressac‐de Paillerets, Brigitte, additional, Burnichon, Nelly, additional, Chiesa, Jean, additional, Giraud, Sophie, additional, Lejeune, Sophie, additional, Limacher, Jean‐Marc, additional, Pauw, Antoine, additional, Stoppa‐Lyonnet, Dominique, additional, Zattara‐Cannoni, Hélène, additional, Deveaux, Sophie, additional, Lidereau, Rosette, additional, Richard, Stéphane, additional, and Rouleau, Etienne, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Association and Performance of Polygenic Risk Scores for Breast Cancer Among French Women Presenting or Not a Familial Predisposition to the Disease
- Author
-
Jiao, Yue, primary, Truong, Thérèse, additional, Eon-Marchais, Séverine, additional, Mebirouk, Noura, additional, Caputo, Sandrine M., additional, Dondon, Marie-Gabrielle, additional, Karimi, Mojgan, additional, Le Gal, Dorothée, additional, Beauvallet, Juana, additional, Le Floch, Edith, additional, Dandine-Roulland, Claire, additional, Bacq-Daian, Delphine, additional, Olaso, Robert, additional, Albuisson, Juliette, additional, Audebert-Bellanger, Séverine, additional, Berthet, Pascaline, additional, Bonadona, Valérie, additional, Buecher, Bruno, additional, Caron, Olivier, additional, Cavaillé, Mathias, additional, Chiesa, Jean, additional, Colas, Chrystelle, additional, Collonge-Rame, Marie-Agnès, additional, Coupier, Isabelle, additional, Delnatte, Capucine, additional, De Pauw, Antoine, additional, Dreyfus, Hélène, additional, Fert-Ferrer, Sandra, additional, Gauthier-Villars, Marion, additional, Gesta, Paul, additional, Giraud, Sophie, additional, Gladieff, Laurence, additional, Golmard, Lisa, additional, Lasset, Christine, additional, Lejeune-Dumoulin, Sophie, additional, Léone, Mélanie, additional, Limacher, Jean-Marc, additional, Lortholary, Alain, additional, Luporsi, Elisabeth, additional, Mari, Véronique, additional, Maugard, Christine M., additional, Mortemousque, Isabelle, additional, Mouret-Fourme, Emmanuelle, additional, Nambot, Sophie, additional, Noguès, Catherine, additional, Popovici, Cornel, additional, Prieur, Fabienne, additional, Pujol, Pascal, additional, Sevenet, Nicolas, additional, Sobol, Hagay, additional, Toulas, Christine, additional, Uhrhammer, Nancy, additional, Vaur, Dominique, additional, Venat, Laurence, additional, Boland-Augé, Anne, additional, Guénel, Pascal, additional, Deleuze, Jean-François, additional, Stoppa-Lyonnet, Dominique, additional, Andrieu, Nadine, additional, and Lesueur, Fabienne, additional
- Published
- 2022
- Full Text
- View/download PDF
20. A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers
- Author
-
Jiao, Yue, Lesueur, Fabienne, Azencott, Chloé-Agathe, Laurent, Maïté, Mebirouk, Noura, Laborde, Lilian, Beauvallet, Juana, Dondon, Marie-Gabrielle, Eon-Marchais, Séverine, Laugé, Anthony, Noguès, Catherine, Andrieu, Nadine, Stoppa-Lyonnet, Dominique, Caputo, Sandrine, Boutry-Kryza, Nadia, Calender, Alain, Giraud, Sophie, Léone, Mélanie, Bressac- de Paillerets, Brigitte, Caron, Olivier, Guillaud-Bataille, Marine, Bignon, Yves-Jean, Uhrhammer, Nancy, Bonadona, Valérie, Lasset, Christine, Berthet, Pascaline, Castera, Laurent, Vaur, Dominique, Bourdon, Violaine, Noguchi, Tetsuro, Popovici, Cornel, Remenieras, Audrey, Sobol, Hagay, Coupier, Isabelle, Harmand, Pierre-Olivier, Pujol, Pascal, Vilquin, Paul, Dumont, Aurélie, Révillion, Françoise, Muller, Danièle, Barouk-Simonet, Emmanuelle, Bonnet, Françoise, Bubien, Virginie, Longy, Michel, Sevenet, Nicolas, Gladieff, Laurence, Guimbaud, Rosine, Feillel, Viviane, Toulas, Christine, Dreyfus, Hélène, Leroux, Dominique, Peysselon, Magalie, Rebischung, Christine, Baurand, Amandine, Bertolone, Geoffrey, Coron, Fanny, Faivre, Laurence, Goussot, Vincent, Jacquot, Caroline, Sawka, Caroline, Kientz, Caroline, Lebrun, Marine, Prieur, Fabienne, Fert-Ferrer, Sandra, Mari, Véronique, Venat-Bouvet, Laurence, Bézieau, Stéphane, Delnatte, Capucine, Mortemousque, Isabelle, Coulet, Florence, Soubrier, Florent, Warcoin, Mathilde, Bronner, Myriam, Lizard, Sarab, Sokolowska, Johanna, Collonge-Rame, Marie-Agnès, Damette, Alexandre, Gesta, Paul, Lallaoui, Hakima, Chiesa, Jean, Molina-Gomes, Denise, Ingster, Olivier, Manouvrier-Hanu, Sylvie, Lejeune, Sophie, Pontois, Pauline, Lyonnet, Dominique Stoppa, Gauthier-Villars, Marion, Buecher, Bruno, Mouret-Fourme, Emmanuelle, Fricker, Jean-Pierre, Luporsi, Elisabeth, Frenay, Marc, Eisinger, Francois, Moretta, Jessica, Dugast, Catherine, Colas, Chrystelle, Lortholary, Alain, Vennin, Philippe, Adenis, Claude, Nguyen, Tan Dat, Rossi, Annick, Tinat, Julie, Tennevet, Isabelle, Limacher, Jean-Marc, Maugard, Christine, Bignon, Jean-Yves, Demange, Liliane, Cohen-Haguenauer, Odile, Gilbert, Brigitte, Zattara-Cannoni, Hélène, Institut Curie [Paris], Université Paris sciences et lettres (PSL), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Bioinformatique (CBIO), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris (UP), Nadia Boutry-Kryza, Alain Calender, Sophie Giraud, Mélanie Léone, Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Bataille, Yves-Jean Bignon, Nancy Uhrhammer, Valérie Bonadona, Christine Lasset, Pascaline Berthet, Laurent Castera, Dominique Vaur, Violaine Bourdon, Catherine Noguès, Tetsuro Noguchi, Cornel Popovici, Audrey Remenieras, Hagay Sobol, Isabelle Coupier, Pierre-Olivier Harmand, Pascal Pujol, Paul Vilquin, Aurélie Dumont, Françoise Révillion, Danièle Muller, Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubien, Michel Longy, Nicolas Sévenet, Laurence Gladieff, Rosine Guimbaud, Viviane Feillel, Christine Toulas, Hélène Dreyfus, Dominique Leroux, Magalie Peysselon, Christine Rebischung, Amandine Baurand, Geoffrey Bertolone, Fanny Coron, Laurence Faivre, Vincent Goussot, Caroline Jacquot, Caroline Sawka, Caroline Kientz, Marine Lebrun, Fabienne Prieur, Sandra Fert-Ferrer, Véronique Mari, Laurence Vénat-Bouvet, Stéphane Bézieau, Capucine Delnatte, Isabelle Mortemousque, Florence Coulet, Florent Soubrier, Mathilde Warcoin, Myriam Bronner, Sarab Lizard, Johanna Sokolowska, Marie-Agnès Collonge-Rame, Alexandre Damette, Paul Gesta, Hakima Lallaoui, Jean Chiesa, Denise Molina-Gomes, Olivier Ingster, Sylvie Manouvrier-Hanu, Sophie Lejeune, Catherine Noguès, Lilian Laborde, Pauline Pontois, Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Olivier Caron, Emmanuelle Mouret-Fourme, Jean-Pierre Fricker, Christine Lasset, Valérie Bonadona, Pascaline Berthet, Laurence Faivre, Elisabeth Luporsi, Marc Frénay, Laurence Gladieff, Paul Gesta, Hagay Sobol, François Eisinger, Jessica Moretta, Michel Longy, Catherine Dugast, Chrystelle Colas, Florent Soubrier, Isabelle Coupier, Pascal Pujol, Alain Lortholary, Philippe Vennin, Claude Adenis, Tan Dat Nguyen, Capucine Delnatte, Annick Rossi, Julie Tinat, Isabelle Tennevet, Jean-Marc Limacher, Christine Maugard, Yves-Jean Bignon, Liliane Demange, Hélène Dreyfus, Odile Cohen-Haguenauer, Brigitte Gilbert, Dominique Leroux, Hélène Zattara-Cannoni, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris Cité (UPCité), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Génétique et évolution des maladies infectieuses (GEMI), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud]), Malbec, Odile, and Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC)
- Subjects
Risk ,Medicine (General) ,Databases, Factual ,Epidemiology ,Computer science ,[SDV]Life Sciences [q-bio] ,Breast Neoplasms ,Health Informatics ,computer.software_genre ,Cohort Studies ,03 medical and health sciences ,Record linkage ,R5-920 ,0302 clinical medicine ,Humans ,Genetic Predisposition to Disease ,Prospective Studies ,030212 general & internal medicine ,AdaBoost ,Supervised machine learning ,BRCA2 Protein ,Linkage (software) ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Database ,BRCA1 Protein ,Random forest ,Support vector machine ,Identifier ,[SDV] Life Sciences [q-bio] ,Identification (information) ,Probabilistic linkage ,Hybrid process ,030220 oncology & carcinogenesis ,Mutation ,Mutation (genetic algorithm) ,Female ,computer ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Research Article - Abstract
Background Linking independent sources of data describing the same individuals enable innovative epidemiological and health studies but require a robust record linkage approach. We describe a hybrid record linkage process to link databases from two independent ongoing French national studies, GEMO (Genetic Modifiers of BRCA1 and BRCA2), which focuses on the identification of genetic factors modifying cancer risk of BRCA1 and BRCA2 mutation carriers, and GENEPSO (prospective cohort of BRCAx mutation carriers), which focuses on environmental and lifestyle risk factors. Methods To identify as many as possible of the individuals participating in the two studies but not registered by a shared identifier, we combined probabilistic record linkage (PRL) and supervised machine learning (ML). This approach (named “PRL + ML”) combined together the candidate matches identified by both approaches. We built the ML model using the gold standard on a first version of the two databases as a training dataset. This gold standard was obtained from PRL-derived matches verified by an exhaustive manual review. Results The Random Forest (RF) algorithm showed a highest recall (0.985) among six widely used ML algorithms: RF, Bagged trees, AdaBoost, Support Vector Machine, Neural Network. Therefore, RF was selected to build the ML model since our goal was to identify the maximum number of true matches. Our combined linkage PRL + ML showed a higher recall (range 0.988–0.992) than either PRL (range 0.916–0.991) or ML (0.981) alone. It identified 1995 individuals participating in both GEMO (6375 participants) and GENEPSO (4925 participants). Conclusions Our hybrid linkage process represents an efficient tool for linking GEMO and GENEPSO. It may be generalizable to other epidemiological studies involving other databases and registries.
- Published
- 2021
- Full Text
- View/download PDF
21. The Breast Cancer-Associated Stromelysin-3 Gene Is Expressed during Mouse Mammary Gland Apoptosis
- Author
-
Lefebvre, Olivier, Wolf, Catherine, Limacher, Jean-Marc, Hutin, Pascal, Wendling, Corinne, LeMeur, Mariane, Basset, Paul, and Rio, Marie-Christine
- Published
- 1992
22. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour
- Author
-
Acres, Bruce, primary, Lacoste, Gisele, additional, and Limacher, Jean-Marc, additional
- Published
- 2015
- Full Text
- View/download PDF
23. A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
- Author
-
Ramlau, Rodryg, Quoix, Elisabeth, Rolski, Janusz, Pless, Miklos, Lena, Herve, Lévy, Eric, Krzakowski, Maciej, Hess, Dagmar, Tartour, Eric, Chenard, Marie-Pierre, Limacher, Jean-Marc, Bizouarne, Nadine, Acres, Bruce, Halluard, Céline, and Velu, Thierry
- Published
- 2008
- Full Text
- View/download PDF
24. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
- Author
-
Oudard, Stéphane, Rixe, Olivier, Beuselinck, Benoit, Linassier, Claude, Banu, Eugeniu, Machiels, Jean-Pascal, Baudard, Marion, Ringeisen, François, Velu, Thierry, Lefrere-Belda, Marie-Aude, Limacher, Jean-Marc, Fridman, W. H., Azizi, Michel, Acres, Bruce, and Tartour, Eric
- Published
- 2011
- Full Text
- View/download PDF
25. Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma
- Author
-
Dummer, Reinhard, Rochlitz, Christoph, Velu, Thierry, Acres, Bruce, Limacher, Jean-Marc, Bleuzen, Pascal, Lacoste, Gisèle, Slos, Philippe, Romero, Pedro, and Urosevic, Mirjana
- Published
- 2008
- Full Text
- View/download PDF
26. Additional file 1 of Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation
- Author
-
Ribeiro Guerra, Maximiliano, Coignard, Juliette, Eon-Marchais, Séverine, Dondon, Marie-Gabrielle, Le Gal, Dorothée, Beauvallet, Juana, Mebirouk, Noura, Belotti, Muriel, Caron, Olivier, Gauthier-Villars, Marion, Coupier, Isabelle, Buecher, Bruno, Lortholary, Alain, Fricker, Jean-Pierre, Gesta, Paul, Noguès, Catherine, Faivre, Laurence, Berthet, Pascaline, Luporsi, Elisabeth, Delnatte, Capucine, Bonadona, Valérie, Maugard, Christine M., Pujol, Pascal, Lasset, Christine, Longy, Michel, Bignon, Yves-Jean, Adenis-Lavignasse, Claude, Venat-Bouvet, Laurence, Dreyfus, Hélène, Gladieff, Laurence, Mortemousque, Isabelle, Audebert-Bellanger, Séverine, Soubrier, Florent, Giraud, Sophie, Lejeune-Dumoulin, Sophie, Limacher, Jean-Marc, Chiesa, Jean, Fajac, Anne, Floquet, Anne, Eisinger, François, Tinat, Julie, Fert-Ferrer, Sandra, Colas, Chrystelle, Frebourg, Thierry, Damiola, Francesca, Barjhoux, Laure, Cavaciuti, Eve, Mazoyer, Sylvie, Tardivon, Anne, Lesueur, Fabienne, Stoppa-Lyonnet, Dominique, and Andrieu, Nadine
- Abstract
Additional file 1. doc includes ‘Supplementary Method Section’ on the eligibility criteria for admission of BC patients to family cancer clinics and DNA repair-related variants identification.
- Published
- 2021
- Full Text
- View/download PDF
27. Additional file 2 of Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation
- Author
-
Ribeiro Guerra, Maximiliano, Coignard, Juliette, Eon-Marchais, Séverine, Dondon, Marie-Gabrielle, Le Gal, Dorothée, Beauvallet, Juana, Mebirouk, Noura, Belotti, Muriel, Caron, Olivier, Gauthier-Villars, Marion, Coupier, Isabelle, Buecher, Bruno, Lortholary, Alain, Fricker, Jean-Pierre, Gesta, Paul, Noguès, Catherine, Faivre, Laurence, Berthet, Pascaline, Luporsi, Elisabeth, Delnatte, Capucine, Bonadona, Valérie, Maugard, Christine M., Pujol, Pascal, Lasset, Christine, Longy, Michel, Bignon, Yves-Jean, Adenis-Lavignasse, Claude, Venat-Bouvet, Laurence, Dreyfus, Hélène, Gladieff, Laurence, Mortemousque, Isabelle, Audebert-Bellanger, Séverine, Soubrier, Florent, Giraud, Sophie, Lejeune-Dumoulin, Sophie, Limacher, Jean-Marc, Chiesa, Jean, Fajac, Anne, Floquet, Anne, Eisinger, François, Tinat, Julie, Fert-Ferrer, Sandra, Colas, Chrystelle, Frebourg, Thierry, Damiola, Francesca, Barjhoux, Laure, Cavaciuti, Eve, Mazoyer, Sylvie, Tardivon, Anne, Lesueur, Fabienne, Stoppa-Lyonnet, Dominique, and Andrieu, Nadine
- Abstract
Additional file 2: doc includes ‘Supplementary tables’. Supplemental Table 1. Comparison of the distribution of the characteristics between the subset of cases and controls with and without sequenced genes. Supplemental Table 2. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy by age at censor. Supplemental Table 3. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy by family history of breast cancer. Supplemental Table 4. Effect of variant carrier status on breast cancer in the GENESIS population. Supplemental Table 5. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy by birth cohort, after imputation of missing data. Supplemental Table 6. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy by age at censoring, after imputation of missing data. Supplemental Table 7. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy by family history of breast cancer and by variant carrier status, after imputation of missing data. Supplemental Table 8. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy stratified by variant carrier status, after imputation of missing data. Supplemental Table 9. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy by status of tumor estrogen receptors, after imputation of missing data. Supplemental Table 10. Effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy among cases diagnosed within 5 years before enrollment in GENESIS. Supplemental Table 11. Sensitivity analyses with varying bounds of OR for the definition of genetic variant group: effect of lifetime chest X-ray exposure (any exposure) on breast cancer risk according to the number of exposures, the age at first exposure and the first full-term pregnancy. Supplemental Table 12. Sensitivity analyses by variants group, excluding variants from the ‘High’ Group in genes individually statistically (or borderline) associated with an increased risk of breast cancer in GENESIS population.
- Published
- 2021
- Full Text
- View/download PDF
28. COVID-19 in Patients with Cancer: A Retrospective Study of 212 Cases from a FrenchSARS-CoV-2 Cluster During the First Wave of theCOVID-19 Pandemic
- Author
-
Martin, Sophie, primary, Kaeuffer, Charlotte, additional, Leyendecker, Pierre, additional, Tuzin, Nicolas, additional, Tazi, Youssef, additional, Schaff-Wendling, Frédérique, additional, Kleinheny, Tiffanie, additional, Husson-Wetzel, Stéphanie, additional, Pamart, Guillaume, additional, Limacher, Jean-Marc, additional, Clerc, Olivier, additional, Dicop, Elise, additional, Kurtz, Jean-Emmanuel, additional, Barthélémy, Philippe, additional, and Gantzer, Justine, additional
- Published
- 2021
- Full Text
- View/download PDF
29. Germline MET pathogenic variants in papillary renal cell carcinomas type I: specific phenotype in French population and novel germline pathogenic variant MET c.3389T>C, p.(Leu1130Ser)
- Author
-
SEBAI, Molka, primary, TULASNE, David, additional, Caputo, Sandrine, additional, VERKARRE, Virginie, additional, FERNANDES, Marie, additional, REINHART, Fanny, additional, ADAMS, Severine, additional, Maugard, Christine, additional, Caron, Olivier, additional, GUILLAUD-BATAILLE, Marine, additional, BERTHET, Pascaline , additional, Bignon, Yves-Jean, additional, Paillerets, Brigitte Bressac-de, additional, BURNICHON, Nelly, additional, Chiesa, Jean, additional, Giraud, Sophie, additional, LEJEUNE, Sophie, additional, LIMACHER, Jean-Marc, additional, Pauw, Antoine de, additional, Stoppa-Lyonnet, Dominique, additional, ZATTARA-CANNONI, Hélène, additional, DEVEAUX, Sophie, additional, LIDEREAU, Rosette, additional, RICHARD, Stéphane, additional, and Rouleau, Etienne, additional
- Published
- 2021
- Full Text
- View/download PDF
30. Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer
- Author
-
Limacher, Jean-Marc, Spring-Giusti, Clémentine, Bellon, Nadine, Ancian, Philippe, Rooke, Ronald, and Bonnefoy, Jean-Yves
- Published
- 2013
- Full Text
- View/download PDF
31. Therapeutic vaccination to treat chronic infectious diseases:: Current clinical developments using MVA-based vaccines
- Author
-
Boukhebza, Houda, Bellon, Nadine, Limacher, Jean Marc, and Inchauspé, Geneviève
- Published
- 2012
32. Gene‐ and pathway‐level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility
- Author
-
Lonjou, Christine, primary, Eon‐Marchais, Séverine, additional, Truong, Thérèse, additional, Dondon, Marie‐Gabrielle, additional, Karimi, Mojgan, additional, Jiao, Yue, additional, Damiola, Francesca, additional, Barjhoux, Laure, additional, Le Gal, Dorothée, additional, Beauvallet, Juana, additional, Mebirouk, Noura, additional, Cavaciuti, Eve, additional, Chiesa, Jean, additional, Floquet, Anne, additional, Audebert‐Bellanger, Séverine, additional, Giraud, Sophie, additional, Frebourg, Thierry, additional, Limacher, Jean‐Marc, additional, Gladieff, Laurence, additional, Mortemousque, Isabelle, additional, Dreyfus, Hélène, additional, Lejeune‐Dumoulin, Sophie, additional, Lasset, Christine, additional, Venat‐Bouvet, Laurence, additional, Bignon, Yves‐Jean, additional, Pujol, Pascal, additional, Maugard, Christine M., additional, Luporsi, Elisabeth, additional, Bonadona, Valérie, additional, Noguès, Catherine, additional, Berthet, Pascaline, additional, Delnatte, Capucine, additional, Gesta, Paul, additional, Lortholary, Alain, additional, Faivre, Laurence, additional, Buecher, Bruno, additional, Caron, Olivier, additional, Gauthier‐Villars, Marion, additional, Coupier, Isabelle, additional, Mazoyer, Sylvie, additional, Monraz, Luis‐Cristobal, additional, Kondratova, Maria, additional, Kuperstein, Inna, additional, Guénel, Pascal, additional, Barillot, Emmanuel, additional, Stoppa‐Lyonnet, Dominique, additional, Andrieu, Nadine, additional, and Lesueur, Fabienne, additional
- Published
- 2021
- Full Text
- View/download PDF
33. Polyglobulie et hypercalcémie associés à un carcinome à cellule rénale : à propos d’un cas et revue de la littérature
- Author
-
Errachi, Hayat, primary, Randriamanovontsoa, Niaina Ezra, additional, Litique, Valère, additional, Amaadour, Lamiae, additional, Oualla, Karima, additional, Benbrahim, Zineb, additional, Mellas, Nawfal, additional, and Limacher, Jean-Marc, additional
- Published
- 2021
- Full Text
- View/download PDF
34. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
- Author
-
Bertolotto, Corine, Lesueur, Fabienne, Giuliano, Sandy, Strub, Thomas, de Lichy, Mahaut, Bille, Karine, Dessen, Philippe, d’Hayer, Benoit, Mohamdi, Hamida, Remenieras, Audrey, Maubec, Eve, de la Fouchardière, Arnaud, Molinié, Vincent, Vabres, Pierre, Dalle, Stéphane, Poulalhon, Nicolas, Martin-Denavit, Tanguy, Thomas, Luc, Andry-Benzaquen, Pascale, Dupin, Nicolas, Boitier, Françoise, Rossi, Annick, Perrot, Jean-Luc, Labeille, Bruno, Robert, Caroline, Escudier, Bernard, Caron, Olivier, Brugières, Laurence, Saule, Simon, Gardie, Betty, Gad, Sophie, Richard, Stéphane, Couturier, Jérôme, Teh, Bin Tean, Ghiorzo, Paola, Pastorino, Lorenza, Puig, Susana, Badenas, Celia, Olsson, Hakan, Ingvar, Christian, Rouleau, Etienne, Lidereau, Rosette, Bahadoran, Philippe, Vielh, Philippe, Corda, Eve, Blanché, Hélène, Zelenika, Diana, Galan, Pilar, Aubin, François, Bachollet, Bertrand, Becuwe, Céline, Berthet, Pascaline, Jean Bignon, Yves, Bonadona, Valérie, Bonafe, Jean-Louis, Bonnet-Dupeyron, Marie-Noëlle, Cambazard, Fréderic, Chevrant-Breton, Jacqueline, Coupier, Isabelle, Dalac, Sophie, Demange, Liliane, d’Incan, Michel, Dugast, Catherine, Faivre, Laurence, Vincent-Fétita, Lynda, Gauthier-Villars, Marion, Gilbert, Brigitte, Grange, Florent, Grob, Jean-Jacques, Humbert, Philippe, Janin, Nicolas, Joly, Pascal, Kerob, Delphine, Lasset, Christine, Leroux, Dominique, Levang, Julien, Limacher, Jean-Marc, Livideanu, Cristina, Longy, Michel, Lortholary, Alain, Stoppa-Lyonnet, Dominique, Mansard, Sandrine, Mansuy, Ludovic, Marrou, Karine, Matéus, Christine, Maugard, Christine, Meyer, Nicolas, Nogues, Catherine, Souteyrand, Pierre, Venat-Bouvet, Laurence, Zattara, Hélène, Chaudru, Valérie, Lenoir, Gilbert M., Lathrop, Mark, Davidson, Irwin, Avril, Marie-Françoise, Demenais, Florence, Ballotti, Robert, and Bressac-de Paillerets, Brigitte
- Published
- 2011
- Full Text
- View/download PDF
35. 793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
- Author
-
Tourneau, Christophe Le, primary, Cassier, Philippe, additional, Rolland, Frederic, additional, Salas, Sébastien, additional, Limacher, Jean Marc, additional, Capitain, Olivier, additional, Lantz, Olivier, additional, Lalanne, Ana, additional, Ekwegbara, Christina, additional, Tavernaro, Annette, additional, Makhloufi, Hakim, additional, Bendjama, Kaidre, additional, and Delord, Jean-Pierre, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
- Author
-
Mavaddat, Nasim, Antoniou, Antonis C., Mooij, Thea M., Hooning, Maartje J., Heemskerk-Gerritsen, Bernadette A., Noguès, Catherine, Gauthier-Villars, Marion, Caron, Olivier, Gesta, Paul, Pujol, Pascal, Lortholary, Alain, Barrowdale, Daniel, Frost, Debra, Evans, D. Gareth, Izatt, Louise, Adlard, Julian, Eeles, Ros, Brewer, Carole, Tischkowitz, Marc, Henderson, Alex, Cook, Jackie, Eccles, Diana, van Engelen, Klaartje, Mourits, Marian J. E., Ausems, Margreet G. E. M., Koppert, Linetta B., Hopper, John L., John, Esther M., Chung, Wendy K., Andrulis, Irene L., Daly, Mary B., Buys, Saundra S., Benitez, Javier, Caldes, Trinidad, Jakubowska, Anna, Simard, Jacques, Singer, Christian F., Tan, Yen, Olah, Edith, Navratilova, Marie, Foretova, Lenka, Gerdes, Anne-Marie, Roos-Blom, Marie-José, Van Leeuwen, Flora E., Arver, Brita, Olsson, Håkan, Schmutzler, Rita K., Engel, Christoph, Kast, Karin, Phillips, Kelly-Anne, Terry, Mary Beth, Milne, Roger L., Goldgar, David E., Rookus, Matti A., Andrieu, Nadine, Easton, Douglas F., Laborde, Lilian, Breysse, Emmanuel, Stoppa-Lyonnet, Dominique, Buecher, Bruno, Fourme-Mouret, Emmanuelle, Fricker, Jean-Pierre, Lasset, Christine, Bonadona, Valérie, Berthet, Pascaline, Faivre, Laurence, Luporsi, Elisabeth, Mari, Véronique, Gladieff, Laurence, Sobol, Hagay, Eisinger, François, Longy, Michel, Dugast, Catherine, Colas, Chrystelle, Coupier, Isabelle, Corsini, Carole, Vennin, Philippe, Adenis, Claude, Nguyen, Tan Dat, Delnatte, Capucine, Tinat, Julie, Tennevet, Isabelle, Limacher, Jean-Marc, Maugard, Christine, Bignon, Yves-Jean, Demange, Liliane, Penet, Clotilde, Dreyfus, Hélène, Cohen-Haguenauer, Odile, Venat-Bouvet, Laurence, Leroux, Dominique, Zattara-Cannoni, Hélène, Fert-Ferrer, Sandra, Bera, Odile, Ellis, Steve, Hogervorst, F. B. L., Collée, J. M., van Asperen, C. J., Mensenkamp, A. R., Ausems, M. G. E. M., Meijers-Heijboer, H. E. J., van Engelen, K., Blok, M. J., Oosterwijk, J. C., Verloop, J., van den Broek, E., Mavaddat, Nasim [0000-0003-0307-055X], and Apollo - University of Cambridge Repository
- Subjects
Risk-reducing salpingo-oophorectomy ,Breast cancer ,endocrine system diseases ,Mutation ,skin and connective tissue diseases ,BRCA1 ,BRCA2 ,Research Article - Abstract
Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods: A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results: There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94–1.61) or BRCA2 (HR = 0.88; 95% CI 0.62–1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40–1.15) and 1.07 (95% CI 0.69–1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26–0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion: We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.
- Published
- 2020
37. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
- Author
-
Bertolotto, Corine, Lesueur, Fabienne, Giuliano, Sandy, Strub, Thomas, de Lichy, Mahaut, Bille, Karine, Dessen, Philippe, d%apos, Hayer, Benoit, Mohamdi, Hamida, Remenieras, Audrey, Maubec, Eve, de la Fouchardière, Arnaud, Molinié, Vincent, Vabres, Pierre, Dalle, Stéphane, Poulalhon, Nicolas, Martin-Denavit, Tanguy, Thomas, Luc, Andry-Benzaquen, Pascale, Dupin, Nicolas, Boitier, Françoise, Rossi, Annick, Perrot, Jean-Luc, Labeille, Bruno, Robert, Caroline, Escudier, Bernard, Caron, Olivier, Brugières, Laurence, Saule, Simon, Gardie, Betty, Gad, Sophie, Richard, Stéphane, Couturier, Jérôme, Teh, Bin Tean, Ghiorzo, Paola, Pastorino, Lorenza, Puig, Susana, Badenas, Celia, Olsson, Hakan, Ingvar, Christian, Rouleau, Etienne, Lidereau, Rosette, Bahadoran, Philippe, Vielh, Philippe, Corda, Eve, Blanché, Hélène, Zelenika, Diana, Galan, Pilar, Aubin, François, Bachollet, Bertrand, Becuwe, Céline, Berthet, Pascaline, Jean Bignon, Yves, Bonadona, Valérie, Bonafe, Jean-Louis, Bonnet-Dupeyron, Marie-Noëlle, Cambazard, Fréderic, Chevrant-Breton, Jacqueline, Coupier, Isabelle, Dalac, Sophie, Demange, Liliane, Incan, Michel, Dugast, Catherine, Faivre, Laurence, Vincent-Fétita, Lynda, Gauthier-Villars, Marion, Gilbert, Brigitte, Grange, Florent, Grob, Jean-Jacques, Humbert, Philippe, Janin, Nicolas, Joly, Pascal, Kerob, Delphine, Lasset, Christine, Leroux, Dominique, Levang, Julien, Limacher, Jean-Marc, Livideanu, Cristina, Longy, Michel, Lortholary, Alain, Stoppa-Lyonnet, Dominique, Mansard, Sandrine, Mansuy, Ludovic, Marrou, Karine, Matéus, Christine, Maugard, Christine, Meyer, Nicolas, Nogues, Catherine, Souteyrand, Pierre, Venat-Bouvet, Laurence, Zattara, Hélène, Chaudru, Valérie, Lenoir, Gilbert M., Lathrop, Mark, Davidson, Irwin, Avril, Marie-Françoise, Demenais, Florence, Ballotti, Robert, and Bressac-de Paillerets, Brigitte
- Abstract
Author(s): Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d%apos;Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; [...]
- Published
- 2016
- Full Text
- View/download PDF
38. MUC1 as a target antigen for cancer immunotherapy
- Author
-
Acres, Bruce and Limacher, Jean-Marc
- Published
- 2005
- Full Text
- View/download PDF
39. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome
- Author
-
BOUGEARD, GAËLLE, LIMACHER, JEAN-MARC, MARTIN, COSETTE, CHARBONNIER, FRANÇOISE, KILLIAN, AUDREY, DELATTRE, OLIVIER, LONGY, MICHEL, JONVEAUX, PHILIPPE, FRICKER, JEAN-PIERRE, STOPPA-LYONNET, DOMINIQUE, FLAMAN, JEAN-MICHEL, and FRÉBOURG, THIERRY
- Published
- 2001
40. COVID‐19 in Patients with Cancer: A Retrospective Study of 212 Cases from a French SARS‐CoV‐2 Cluster During the First Wave of the COVID‐19 Pandemic.
- Author
-
Martin, Sophie, Kaeuffer, Charlotte, Leyendecker, Pierre, Tuzin, Nicolas, Tazi, Youssef, Schaff‐Wendling, Frédérique, Kleinheny, Tiffanie, Husson‐Wetzel, Stéphanie, Pamart, Guillaume, Limacher, Jean‐Marc, Clerc, Olivier, Dicop, Elise, Kurtz, Jean‐Emmanuel, Barthélémy, Philippe, and Gantzer, Justine
- Subjects
TUMOR treatment ,RESEARCH ,COVID-19 ,RETROSPECTIVE studies ,MEDICAL cooperation ,CANCER patients ,RADIOTHERAPY ,COVID-19 pandemic ,IMMUNOTHERAPY - Abstract
We describe a large series of patients with solid tumors in an early COVID‐19 cluster in the eastern part of France. From February to May 2020, this multicenter retrospective study enrolled 212 patients with cancer under treatment or on follow‐up for any type of malignant solid tumor and positive for SARS‐CoV‐2. The mortality rate was 30%. Patients with gastrointestinal cancers were identified as a subset of more vulnerable patients; immunotherapy and radiotherapy within 3 months from COVID‐19 diagnosis were risk factors for death. The reported data support the essential need to be proactive and weigh the risks of morbidity from COVID‐19 against the magnitude of benefits of intended cancer therapies during this pandemic. Implications for Practice: This article supports the essential need to be proactive (treatment delay or modification) in oncology in the setting of pandemic. This study identified patients with gastrointestinal cancers as a more vulnerable subset of patients with cancer and found that immunotherapy and radiotherapy within 3 months from COVID‐19 diagnosis to be risk factors for death. The reported data indicate the necessity of weighing the risks of morbidity from COVID‐19 against the magnitude of benefits of intended cancer therapies in any future wave of COVID‐19. In the light of a local experience in an area of France, this article describes disease characteristics, management, and outcomes in patients with cancer and confirmed or highly suspected COVID‐19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing
- Author
-
Girard, Elodie, Eon-Marchais, Séverine, Olaso, François, Renault, Anne, Damiola, Francesca, Dondon, Marie-Gabrielle, Barjhoux, Laure, Goidin, Didier, Meyer, François, Le Gal, Dorothée, Beauvallet, Juana, Mebirouk, Noura, Lonjou, Christine, Coignard, Julie, Marcou, Morgane, Cavaciuti, Eve, Baulard, François, Bihoreau, François, Cohen-Haguenauer, Odile, Leroux, Dominique, Penet, Jean, Fert-Ferrer, Sandra, Colas, Chrystelle, Frebourg, Thierry, Eisinger, François, Adenis, Claude, Fajac, Anne, Gladieff, Laurence, Tinat, Julie, Floquet, Anne, Chiesa, Jean, Giraud, Sophie, Mortemousque, Isabelle, Soubrier, Florent, Audebert-Bellanger, Séverine, Limacher, Jean-Marc, Lasset, Christine, Lejeune-Dumoulin, Sophie, Dreyfus, Catherine, Bignon, Yves-Jean, Longy, Michel, Pujol, Pascal, Venat-Bouvet, Laurence, Bonadona, Valérie, Berthet, Pascaline, Luporsi, Elisabeth, Maugard, Christine, Noguès, Catherine, Delnatte, Capucine, Fricker, Paul, Gesta, Paul, Faivre, Laurence, Lortholary, Alain, Buecher, Bruno, Caron, Olivier, Gauthier-Villars, Marion, Coupier, Isabelle, Servant, Nicolas, Boland, Anne, Mazoyer, Sylvie, Deleuze, Jean-François, Stoppa-Lyonnet, Dominique, Andrieu, Nadine, Lesueur, Fabienne, Université Paris sciences et lettres (PSL), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Léon Bérard [Lyon]-Hospices Civils de Lyon (HCL), Life Sciences and Diagnostics Group [Les Ulis, France], Agilent Technologies France, Laboratoire Information, Milieux, Médias, Médiations - EA 3820 (I3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université de Toulon (UTLN), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Traitement Algorithmique et Matériel de la Communication, de l'Information et de la Connaissance (TAMCIC), Ecole Nationale Supérieure des Télécommunications de Bretagne-Centre National de la Recherche Scientifique (CNRS), CRLCC Jean Godinot, Centre Hospitalier de Chambéry (C.H.de Chambéry), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Département de Génétique [Institut Curie, Paris] (Unité de Pharmacogénomique), Institut Curie [Paris], Génétique médicale et fonctionnelle du cancer et des maladies neuropsychiatriques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Claudius Regaud, Service de génétique [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département d'oncologie médicale, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Laboratoire de Cytogénétique, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Service de génétique [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Génétique épidémiologique et moléculaire des pathologies cardiovasculaires, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Génétique Moléculaire et d'Histocompatibilité [Brest], Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital pasteur [Colmar], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Sainte Catherine [Avignon], Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Département de pathologie, Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Dupuytren [CHU Limoges], Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Consultation d'Oncogénétique, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Alexis Vautrin (CAV), Laboratoire de Diagnostic Génétique [CHU Strasbourg], Université de Strasbourg (UNISTRA)-CHU Strasbourg, Laboratoire d'Oncogénétique, CRLCC René Huguenin, CRLCC René Gauducheau, Service d'Oncologie Médicale [Strasbourg] (UNICANCER Centre Paul Strauss), Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC), Centre Hospitalier Georges Renon [Niort] (CH Georges Renon Niort), Génétique des Anomalies du Développement (GAD), Université de Bourgogne (UB)-IFR100 - Structure fédérative de recherche Santé-STIC, Centre Catherine-de-Sienne [Nantes] (CCS), Service de Génétique Oncologique, Onco-génétique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Unité d'Oncogénétique, CRLCC Val d'Aurelle - Paul Lamarque, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Unité de génétique et biologie des cancers (U830), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Grant sponsor: comprehensive cancer center SiRIC, Grant numbers: INCa-DGOS-4654, Grant sponsor: Fondation ARC pour la recherche sur le cancer, Grant numbers: PJA 20151203365, Grant sponsor: France Génomique National infrastructure, Grant numbers: ANR-10-INBS-09, Grant sponsor: Institut National du Cancer (INCa), Grant numbers: b2008-029/LL-LC, Grant sponsor: Ligue Comité de Paris, Grant numbers: RS15/75-78, Grant sponsor: Ligue Nationale Contre le Cancer, Grant numbers: PRE05/DSL PRE07/DSL PRE11/NA., Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Cancer et génôme: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris-Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de génétique et de physiologie moléculaire et cellulaire (CGPhiMC), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Epidémiologie des cancers : Radiocarcinogénèse et effets iatrogènes des traitements, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), E06, Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Léon Bérard [Lyon]-Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Plateforme Post-génomique de la Pitié-Salpêtrière (P3S), UMS omique (OMIQUE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), CRESS, Université de Franche-Comté (UFC), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service de génétique médicale CHU Grenoble Hôpital Couple Enfant, CHU Grenoble, CHU Saint-Antoine [APHP], Génétique du cancer et des maladies neuropsychiatriques (GMFC), Centre oscar lambert, service d'hématologie chu, CHU Tenon [APHP], CRLCC Institut Claudius Regaud, Centre Beninois pour l'Environnement et le développement économique et Social (CEBEDES), Service de Génétique Clinique [CHRU Nïmes], Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Service de Pédiatrie et de Génétique Médicale, Hôpital Jeanne de Flandre [Lille], Imagerie Moléculaire et Stratégies Théranostiques - Clermont Auvergne (IMoST), Université Clermont Auvergne (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Jean Perrin, CRLCC Jean Perrin, Institut Bergonié - CRLCC Bordeaux, Service d'Oncologie médicale [CHU Limoges], CHU Limoges, Génétique épidémiologique et structures des populations humaines (Inserm U535), Epidémiologie, sciences sociales, santé publique (IFR 69), Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Laboratoire de diagnostic génétique, Hôpital Universitaire de Strasbourg, Strasbourg, Centre René Gauducheau, Genetic and Immunology Medical Institute (GIMI), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Fédération Francophone de la Cancérologie Digestive, FFCD, Institut Gustave Roussy (IGR), Service d'oncogénétique, Institut Curie, Service de génétique médicale [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Equipe 6, Université Paris Descartes - Paris 5 (UPD5), Méthodologie statistique et épidémiologie génétique des maladies multifactorielles, Institut National de la Santé et de la Recherche Médicale (INSERM), Section Génétique - Groupe Prédispositions génétiques au cancer, Centre International de Recherche contre le Cancer (CIRC), MINES ParisTech - École nationale supérieure des mines de Paris, Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (... - 2019) (UNS), Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure des Télécommunications de Bretagne, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Lille Nord de France (COMUE)-UNICANCER, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Andrieu, Nadine, Institut Curie [Paris]-MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)
- Subjects
Adult ,DNA Repair ,case-control study ,[SDV]Life Sciences [q-bio] ,Breast Neoplasms ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.GEN] Life Sciences [q-bio]/Genetics ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,Risk Assessment ,Cancer Genetics and Epigenetics ,breast cancer ,multigene panel testing ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Aged ,Aged, 80 and over ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,Siblings ,case–control study ,Middle Aged ,[SDV] Life Sciences [q-bio] ,variant ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Case-Control Studies ,Female ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,exome sequencing - Abstract
Pathogenic variants in BRCA1 and BRCA2 only explain the underlying genetic cause of about 10% of hereditary breast and ovarian cancer families. Because of cost‐effectiveness, multigene panel testing is often performed even if the clinical utility of testing most of the genes remains questionable. The purpose of our study was to assess the contribution of rare, deleterious‐predicted variants in DNA repair genes in familial breast cancer (BC) in a well‐characterized and homogeneous population. We analyzed 113 DNA repair genes selected from either an exome sequencing or a candidate gene approach in the GENESIS study, which includes familial BC cases with no BRCA1 or BRCA2 mutation and having a sister with BC (N = 1,207), and general population controls (N = 1,199). Sequencing data were filtered for rare loss‐of‐function variants (LoF) and likely deleterious missense variants (MV). We confirmed associations between LoF and MV in PALB2, ATM and CHEK2 and BC occurrence. We also identified for the first time associations between FANCI, MAST1, POLH and RTEL1 and BC susceptibility. Unlike other associated genes, carriers of an ATM LoF had a significantly higher risk of developing BC than carriers of an ATM MV (ORLoF = 17.4 vs. ORMV = 1.6; p Het = 0.002). Hence, our approach allowed us to specify BC relative risks associated with deleterious‐predicted variants in PALB2, ATM and CHEK2 and to add MAST1, POLH, RTEL1 and FANCI to the list of DNA repair genes possibly involved in BC susceptibility. We also highlight that different types of variants within the same gene can lead to different risk estimates., What's new? Pathogenic variants in BRCA1 and BRCA2 only explain the genetic cause of about 10% of hereditary breast and ovarian cancer families, and the clinical usefulness of testing other genes following the recent introduction of cost‐effective multigene panel sequencing in diagnostics laboratories remains questionable. This large case‐control study describes genetic variation in 113 DNA repair genes and specifies breast cancer relative risks associated with rare deleterious‐predicted variants in PALB2, ATM, and CHEK2. Importantly, different types of variants within the same gene can lead to different risk estimates. The results may help improve risk prediction models and define gene‐specific consensus management guidelines.
- Published
- 2019
- Full Text
- View/download PDF
42. The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up
- Author
-
Harper, Diane M., primary, Nieminen, Pekka, additional, Donders, Gilbert, additional, Einstein, Mark H., additional, Garcia, Francisco, additional, Huh, Warner K., additional, Stoler, Mark H., additional, Glavini, Katerina, additional, Attley, Gemma, additional, Limacher, Jean-Marc, additional, Bastien, Berangere, additional, and Calleja, Elizabeth, additional
- Published
- 2019
- Full Text
- View/download PDF
43. An innovative combined immunization platform for personalized cancer immunotherapy.
- Author
-
Matta, Jessica, primary, Matta, Célia, additional, Thiebault Peter, Emilie, additional, Moulaert, David, additional, Drillien, Robert, additional, Petit-Demouliere, Benoit, additional, Sorg, Tania, additional, Bou about, Ghina, additional, and Limacher, Jean-Marc, additional
- Published
- 2019
- Full Text
- View/download PDF
44. Familial non-VHL non-papillary clear-cell renal cancer
- Author
-
Teh, Bin Tean, Giraud, Sophie, Sari, Nora Fatiha, Hii, Su Ing, Bergerat, Jean Pierre, Larsson, Catharina, Limacher, Jean Marc, and Nicol, David
- Published
- 1997
45. LA START-UP QUI RÉVOLUTIONNE LA MÉDECINE PERSONNALISÉE dans le domaine de l'oncologie.
- Author
-
Balducchi, Pascale and Limacher, Jean-Marc
- Published
- 2024
46. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing
- Author
-
Girard, Elodie, primary, Eon‐Marchais, Séverine, additional, Olaso, Robert, additional, Renault, Anne‐Laure, additional, Damiola, Francesca, additional, Dondon, Marie‐Gabrielle, additional, Barjhoux, Laure, additional, Goidin, Didier, additional, Meyer, Vincent, additional, Le Gal, Dorothée, additional, Beauvallet, Juana, additional, Mebirouk, Noura, additional, Lonjou, Christine, additional, Coignard, Juliette, additional, Marcou, Morgane, additional, Cavaciuti, Eve, additional, Baulard, Céline, additional, Bihoreau, Marie‐Thérèse, additional, Cohen‐Haguenauer, Odile, additional, Leroux, Dominique, additional, Penet, Clotilde, additional, Fert‐Ferrer, Sandra, additional, Colas, Chrystelle, additional, Frebourg, Thierry, additional, Eisinger, François, additional, Adenis, Claude, additional, Fajac, Anne, additional, Gladieff, Laurence, additional, Tinat, Julie, additional, Floquet, Anne, additional, Chiesa, Jean, additional, Giraud, Sophie, additional, Mortemousque, Isabelle, additional, Soubrier, Florent, additional, Audebert‐Bellanger, Séverine, additional, Limacher, Jean‐Marc, additional, Lasset, Christine, additional, Lejeune‐Dumoulin, Sophie, additional, Dreyfus, Hélène, additional, Bignon, Yves‐Jean, additional, Longy, Michel, additional, Pujol, Pascal, additional, Venat‐Bouvet, Laurence, additional, Bonadona, Valérie, additional, Berthet, Pascaline, additional, Luporsi, Elisabeth, additional, Maugard, Christine M., additional, Noguès, Catherine, additional, Delnatte, Capucine, additional, Fricker, Jean‐Pierre, additional, Gesta, Paul, additional, Faivre, Laurence, additional, Lortholary, Alain, additional, Buecher, Bruno, additional, Caron, Olivier, additional, Gauthier‐Villars, Marion, additional, Coupier, Isabelle, additional, Servant, Nicolas, additional, Boland, Anne, additional, Mazoyer, Sylvie, additional, Deleuze, Jean‐François, additional, Stoppa‐Lyonnet, Dominique, additional, Andrieu, Nadine, additional, and Lesueur, Fabienne, additional
- Published
- 2018
- Full Text
- View/download PDF
47. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations
- Author
-
Terry, Mary Beth, Liao, Yuyan, Kast, Karin, Antoniou, Antonis C., McDonald, Jasmine A., Mooij, Thea M., Engel, Christoph, Nogues, Catherine, Buecher, Bruno, Mari, Veronique, Moretta-Serra, Jessica, Gladieff, Laurence, Luporsi, Elisabeth, Barrowdale, Daniel, Frost, Debra, Henderson, Alex, Brewer, Carole, Evans, D. Gareth, Eccles, Diana, Cook, Jackie, Ong, Kai-ren, Izatt, Louise, Ahmed, Munaza, Morrison, Patrick J., Dommering, Charlotte J., Oosterwijk, Jan C., Ausems, Margreet G. E. M., Kriege, Mieke, Buys, Saundra S., Andrulis, Irene L., John, Esther M., Daly, Mary, Friedlander, Michael, McLachlan, Sue Anne, Osorio, Ana, Caldes, Trinidad, Jakubowska, Anna, Simard, Jacques, Singer, Christian F., Tan, Yen, Olah, Edith, Navratilova, Marie, Foretova, Lenka, Gerdes, Anne-Marie, Roos-Blom, Marie-Jose, Arver, Brita, Olsson, Hakan, Schmutzler, Rita K., Hopper, John L., van Leeuwen, Flora E., Goldgar, David, Milne, Roger L., Easton, Douglas F., Rookus, Matti A., Andrieu, Nadine, Evans, Gareth, Adlard, Julian, Eeles, Ros, Davidson, Rosemarie, Tischkowitz, Marc, Snape, Katie, Walker, Lisa, Porteous, Mary, Donaldson, Alan, Morrison, Patrick, Eason, Jacqueline, Rogers, Mark, Miller, Claire, Brady, Angela, Kennedy, M. John, Barwell, Julian, Gregory, Helen, Pottinger, Caroline, Murray, Alex, Angelakos, Maggie, Dite, Gillian, Tsimiklis, Helen, Breysse, Emmanuel, Pontois, Pauline, Laborde, Lilian, Stoppa-Lyonnet, Dominique, Gauthier-Villars, Marion, Caron, Olivier, Fourme-Mouret, Emmanuelle, Fricker, Jean-Pierre, Lasset, Christine, Bonadona, Valerie, Fert-Ferrer, Sandra, Berthet, Pascaline, Venat-Bouvet, Laurence, Gilbert-Dussardier, Brigitte, Faivre, Laurence, Gesta, Paul, Sobol, Hagay, Eisinger, Francois, Longy, Michel, Dugast, Catherine, Coupier, Isabelle, Colas, Chrystelle, Soubrier, Florent, Pujol, Pascal, Corsini, Carole, Lortholary, Alain, Vennin, Philippe, Adenis, Claude, Penet, Clotilde, Delnatte, Capucine, Tinat, Julie, Tennevet, Isabelle, Limacher, Jean-Marc, Maugard, Christine, Demange, Liliane, Dreyfus, Helene, Cohen-Haguenauer, Odile, Leroux, Dominique, Zattara-Cannoni, Helene, Bera, Odile, Hogervorst, F. B. L., Adank, M. A., Schmidt, M. K., Russell, N. S., Jenner, D. J., Collee, J. M., van den Ouweland, A. M. W., Hooning, M. J., Seynaeve, C. M., van Deurzen, C. H. M., Obdeijn, I. M., van Asperen, C. J., Devilee, P., Kets, C. M., Mensenkamp, A. R., Koudijs, M. J., Aalfs, C. M., van Engelen, K., Gille, J. J. P., Gomez-Garcia, E. B., Blok, M. J., van der Hout, A. H., Mourits, M. J., de Bock, G. H., Siesling, S., Verloop, J., van den Belt-Dusebout, A. W., Terry, Mary Beth, Liao, Yuyan, Kast, Karin, Antoniou, Antonis C., McDonald, Jasmine A., Mooij, Thea M., Engel, Christoph, Nogues, Catherine, Buecher, Bruno, Mari, Veronique, Moretta-Serra, Jessica, Gladieff, Laurence, Luporsi, Elisabeth, Barrowdale, Daniel, Frost, Debra, Henderson, Alex, Brewer, Carole, Evans, D. Gareth, Eccles, Diana, Cook, Jackie, Ong, Kai-ren, Izatt, Louise, Ahmed, Munaza, Morrison, Patrick J., Dommering, Charlotte J., Oosterwijk, Jan C., Ausems, Margreet G. E. M., Kriege, Mieke, Buys, Saundra S., Andrulis, Irene L., John, Esther M., Daly, Mary, Friedlander, Michael, McLachlan, Sue Anne, Osorio, Ana, Caldes, Trinidad, Jakubowska, Anna, Simard, Jacques, Singer, Christian F., Tan, Yen, Olah, Edith, Navratilova, Marie, Foretova, Lenka, Gerdes, Anne-Marie, Roos-Blom, Marie-Jose, Arver, Brita, Olsson, Hakan, Schmutzler, Rita K., Hopper, John L., van Leeuwen, Flora E., Goldgar, David, Milne, Roger L., Easton, Douglas F., Rookus, Matti A., Andrieu, Nadine, Evans, Gareth, Adlard, Julian, Eeles, Ros, Davidson, Rosemarie, Tischkowitz, Marc, Snape, Katie, Walker, Lisa, Porteous, Mary, Donaldson, Alan, Morrison, Patrick, Eason, Jacqueline, Rogers, Mark, Miller, Claire, Brady, Angela, Kennedy, M. John, Barwell, Julian, Gregory, Helen, Pottinger, Caroline, Murray, Alex, Angelakos, Maggie, Dite, Gillian, Tsimiklis, Helen, Breysse, Emmanuel, Pontois, Pauline, Laborde, Lilian, Stoppa-Lyonnet, Dominique, Gauthier-Villars, Marion, Caron, Olivier, Fourme-Mouret, Emmanuelle, Fricker, Jean-Pierre, Lasset, Christine, Bonadona, Valerie, Fert-Ferrer, Sandra, Berthet, Pascaline, Venat-Bouvet, Laurence, Gilbert-Dussardier, Brigitte, Faivre, Laurence, Gesta, Paul, Sobol, Hagay, Eisinger, Francois, Longy, Michel, Dugast, Catherine, Coupier, Isabelle, Colas, Chrystelle, Soubrier, Florent, Pujol, Pascal, Corsini, Carole, Lortholary, Alain, Vennin, Philippe, Adenis, Claude, Penet, Clotilde, Delnatte, Capucine, Tinat, Julie, Tennevet, Isabelle, Limacher, Jean-Marc, Maugard, Christine, Demange, Liliane, Dreyfus, Helene, Cohen-Haguenauer, Odile, Leroux, Dominique, Zattara-Cannoni, Helene, Bera, Odile, Hogervorst, F. B. L., Adank, M. A., Schmidt, M. K., Russell, N. S., Jenner, D. J., Collee, J. M., van den Ouweland, A. M. W., Hooning, M. J., Seynaeve, C. M., van Deurzen, C. H. M., Obdeijn, I. M., van Asperen, C. J., Devilee, P., Kets, C. M., Mensenkamp, A. R., Koudijs, M. J., Aalfs, C. M., van Engelen, K., Gille, J. J. P., Gomez-Garcia, E. B., Blok, M. J., van der Hout, A. H., Mourits, M. J., de Bock, G. H., Siesling, S., Verloop, J., and van den Belt-Dusebout, A. W.
- Abstract
Background: Full-term pregnancy (FTP) is associated with a reduced breast cancer (BC) risk over time, but women are at increased BC risk in the immediate years following an FTP. No large prospective studies, however, have examined whether the number and timing of pregnancies are associated with BC risk for BRCA1 and BRCA2 mutation carriers. Methods: Using weighted and time-varying Cox proportional hazards models, we investigated whether reproductive events are associated with BC risk for mutation carriers using a retrospective cohort (5707 BRCA1 and 3525 BRCA2 mutation carriers) and a prospective cohort (2276 BRCA1 and 1610 BRCA2 mutation carriers), separately for each cohort and the combined prospective and retrospective cohort. Results: For BRCA1 mutation carriers, there was no overall association with parity compared with nulliparity (combined hazard ratio [HRc] = 0.99, 95% confidence interval [CI] = 0.83 to 1.18). Relative to being uniparous, an increased number of FTPs was associated with decreased BC risk (HRc = 0.79, 95% CI = 0.69 to 0.91; HRc =0.70, 95% CI = 0.59 to 0.82; HRc = 0.50, 95% CI = 0.40 to 0.63, for 2, 3, and >= 4 FTPs, respectively, P-trend < .0001) and increasing duration of breastfeeding was associated with decreased BC risk (combined cohort P-trend = .0003). Relative to being nulliparous, uniparous BRCA1 mutation carriers were at increased BC risk in the prospective analysis (prospective hazard ration [HRp] =1.69, 95% CI =1.09 to 2.62). For BRCA2 mutation carriers, being parous was associated with a 30% increase in BC risk (HRc =1.33, 95% CI =1.05 to 1.69), and there was no apparent decrease in risk associated with multiparity except for having at least 4 FTPs vs. 1 FTP (HRc =0.72, 95% CI = 0.54 to 0.98). Conclusions: These findings suggest differential associations with parity between BRCA1 and BRCA2 mutation carriers with higher risk for uniparous BRCA1 carriers and parous BRCA2 carriers.
- Published
- 2018
48. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
- Author
-
Tosch, Caroline, primary, Bastien, Bérangère, additional, Barraud, Luc, additional, Grellier, Benoit, additional, Nourtier, Virginie, additional, Gantzer, Murielle, additional, Limacher, Jean Marc, additional, Quemeneur, Eric, additional, Bendjama, Kaïdre, additional, and Préville, Xavier, additional
- Published
- 2017
- Full Text
- View/download PDF
49. Trial Watch
- Author
-
Pol, Jonathan, Bloy, Norma, Obrist, Florine, Eggermont, Alexander, Galon, Jérôme, Cremer, Isabelle, Erbs, Philippe, Limacher, Jean-Marc, Preville, Xavier, Zitvogel, Laurence, Kroemer, Guido, and Galluzzi, Lorenzo
- Subjects
MV-NIS ,mesenchymal stem cells ,talimogene laherparepvec ,ColoAd1 ,reolysin ,Review ,adenovirus - Abstract
Oncolytic viruses are natural or genetically modified viral species that selectively infect and kill neoplastic cells. Such an innate or exogenously conferred specificity has generated considerable interest around the possibility to employ oncolytic viruses as highly targeted agents that would mediate cancer cell-autonomous anticancer effects. Accumulating evidence, however, suggests that the therapeutic potential of oncolytic virotherapy is not a simple consequence of the cytopathic effect, but strongly relies on the induction of an endogenous immune response against transformed cells. In line with this notion, superior anticancer effects are being observed when oncolytic viruses are engineered to express (or co-administered with) immunostimulatory molecules. Although multiple studies have shown that oncolytic viruses are well tolerated by cancer patients, the full-blown therapeutic potential of oncolytic virotherapy, especially when implemented in the absence of immunostimulatory interventions, remains unclear. Here, we cover the latest advances in this active area of translational investigation, summarizing high-impact studies that have been published during the last 12 months and discussing clinical trials that have been initiated in the same period to assess the therapeutic potential of oncolytic virotherapy in oncological indications.
- Published
- 2014
50. Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer
- Author
-
Fend, Laetitia, primary, Rusakiewicz, Sylvie, additional, Adam, Julien, additional, Bastien, Bérangère, additional, Caignard, Anne, additional, Messaoudene, Meriem, additional, Iribarren, Christina, additional, Cremer, Isabelle, additional, Marabelle, Aurélien, additional, Borg, Christophe, additional, Semeraro, Michaela, additional, Barraud, Luc, additional, Limacher, Jean-Marc, additional, Eggermont, Alexander, additional, Kroemer, Guido, additional, and Zitvogel, Laurence, additional
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.